News | July 28, 2010

Medicare Radiopharmaceutical Coding, Payment Policy Corrected

July 28, 2010 – The Council on Radionuclides and Radiopharmaceuticals (CORAR) applauded a recent decision by a Medicare administrative to correct coding, coverage and payment policies for radiopharmaceuticals used with myocardial perfusion imaging procedures.

The contractor, Trailblazer Health Enterprises LLC, updated language regarding billing for technetium diagnostic radiopharmaceuticals (A9500) and (A9502) used in multiple myocardial perfusion imaging studies (CPT 78452), which incorrectly limited payment to one dose.

“For the past several years, CORAR members and the Society of Nuclear Medicine (SNM), the American College of Radiology (ACR), the American College of Cardiology (ACC), and the American Society of Nuclear Cardiology (ASNC) have requested that Trailblazer adjust its policy so that providers may bill and be appropriately reimbursed when two technetium heart agent radiopharmaceutical doses are administered consistent with appropriate clinical practice guidelines,” said Michael Guastella, current chairman of the CORAR Healthcare Policy Committee for Reimbursement.

Guastella said the policy in question was inconsistent with good clinical practice and hospital and pharmacy standards. CORAR worked with the medical specialty societies to bring this issue to the attention of CMS. In a letter dated May 21, CORAR brought this issue to the attention of the deputy regional administrator for the Dallas Regional Office of the Centers for Medicare and Medicaid Services (CMS). In response, CMS’s Division of Financial Management and Fee for Service Operations, Region VI consulted with clinical and policy staff at the CMS Central Office and contacted Trailblazer’s medical director. In response to CORAR’s letter the CMS Regional Office communicated that Trailblazer would be withdrawing the language regarding billing for more than one unit of technetium heart agent radiopharmaceutical (A9500) and (A9502) and no longer limit billing to a single dose.

“We believe that this change will allow providers to bill appropriately for the diagnostic radiopharmaceuticals administered while being consistent with Medicare HCPCS coding guidelines, clinical standards and product labeling standards.” said Gail Daubert of ReedSmith, legal counsel to CORAR.

CORAR is an industry trade association comprised of North American manufacturers, developers and suppliers of radiopharmaceuticals and radionuclides primarily used in nuclear medicine and life science research.

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init